On June 20, 2022 Redx (AIM: REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, reported that preclinical data from three of the Company’s proprietary compounds will be presented at the Extracellular Matrix Pharmacology Congress ("ECM"), being held in Copenhagen, Denmark, 23rd-25th June 2022 (Press release, Redx Pharma, JUN 20, 2022, View Source [SID1234616100]). The two presentations cover data originating from Redx collaborations with prestigious international research institutes, the Garvan Institute of Medical Research ("the Garvan"), Australia and Ghent University, Belgium.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The first presentation will highlight preclinical data from Redx’s ongoing collaboration with the Garvan demonstrating the efficacy of targeting fibrosis associated with pancreatic cancer in mouse models with Redx’s Porcupine inhibitor, RXC004, and a Redx proprietary ROCK2 selective inhibitor. The second presentation will detail results from a research collaboration with scientists at Ghent University assessing the efficacy of RXC008, a GI-targeted ROCK inhibitor, to suppress fibrosis as measured by histopathology and magnetic resonance imaging (MRI).
Title: Investigation of novel therapeutic targets in pancreatic cancerassociated fibrosis
Day/Date: Thursday 23 June 2022, 12:45-13:30 CEST
Title: RXC008 suppresses fibrosis in a DSS model as measured by histopathology and magnetic resonance imaging
Day/Date: Saturday 25 June 2022, 13:35-13:45 CEST
The final program is available on the ECM website at: View Source
About the Extracellular Matrix Pharmacology Congress
Redx is one of eight symposium sponsors of the ECM Congress, organised by the Danish Research Foundation. The Congress will bring together experts in the fields of cancer, fibrosis and immunology to discuss new pharmacological approaches to treat chronic diseases often caused by alterations in the extracellular matrix ("ECM") structure